338 results on '"Magi-Galluzzi C"'
Search Results
2. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling
- Author
-
Klein, EA, Cooperberg, MR, Magi-Galluzzi, C, Simko, JP, Falzarano, SM, Maddala, T, Chan, JM, Li, J, Cowan, JE, Tsiatis, AC, Cherbavaz, DB, Pelham, RJ, Tenggara-Hunter, I, Baehner, FL, Knezevic, D, Febbo, PG, Shak, S, Kattan, MW, Lee, M, and Carroll, PR
- Subjects
Clinical Sciences ,Urology & Nephrology - Abstract
Background Prostate tumor heterogeneity and biopsy undersampling pose challenges to accurate, individualized risk assessment for men with localized disease. Objective To identify and validate a biopsy-based gene expression signature that predicts clinical recurrence, prostate cancer (PCa) death, and adverse pathology. Design, setting, and participants Gene expression was quantified by reverse transcription-polymerase chain reaction for three studies - a discovery prostatectomy study (n = 441), a biopsy study (n = 167), and a prospectively designed, independent clinical validation study (n = 395) - testing retrospectively collected needle biopsies from contemporary (1997-2011) patients with low to intermediate clinical risk who were candidates for active surveillance (AS). Outcome measures and statistical analysis The main outcome measures defining aggressive PCa were clinical recurrence, PCa death, and adverse pathology at prostatectomy. Cox proportional hazards regression models were used to evaluate the association between gene expression and time to event end points. Results from the prostatectomy and biopsy studies were used to develop and lock a multigene-expression-based signature, called the Genomic Prostate Score (GPS); in the validation study, logistic regression was used to test the association between the GPS and pathologic stage and grade at prostatectomy. Decision-curve analysis and risk profiles were used together with clinical and pathologic characteristics to evaluate clinical utility. Results and limitations Of the 732 candidate genes analyzed, 288 (39%) were found to predict clinical recurrence despite heterogeneity and multifocality, and 198 (27%) were predictive of aggressive disease after adjustment for prostate-specific antigen, Gleason score, and clinical stage. Further analysis identified 17 genes representing multiple biological pathways that were combined into the GPS algorithm. In the validation study, GPS predicted high-grade (odds ratio [OR] per 20 GPS units: 2.3; 95% confidence interval [CI], 1.5-3.7; p < 0.001) and high-stage (OR per 20 GPS units: 1.9; 95% CI, 1.3-3.0; p = 0.003) at surgical pathology. GPS predicted high-grade and/or high-stage disease after controlling for established clinical factors (p < 0.005) such as an OR of 2.1 (95% CI, 1.4-3.2) when adjusting for Cancer of the Prostate Risk Assessment score. A limitation of the validation study was the inclusion of men with low-volume intermediate-risk PCa (Gleason score 3 + 4), for whom some providers would not consider AS. Conclusions Genes representing multiple biological pathways discriminate PCa aggressiveness in biopsy tissue despite tumor heterogeneity, multifocality, and limited sampling at time of biopsy. The biopsy-based 17-gene GPS improves prediction of the presence or absence of adverse pathology and may help men with PCa make more informed decisions between AS and immediate treatment. Patient summary Prostate cancer (PCa) is often present in multiple locations within the prostate and has variable characteristics. We identified genes with expression associated with aggressive PCa to develop a biopsy-based, multigene signature, the Genomic Prostate Score (GPS). GPS was validated for its ability to predict men who have high-grade or high-stage PCa at diagnosis and may help men diagnosed with PCa decide between active surveillance and immediate definitive treatment. © 2014 European Association of Urology.
- Published
- 2014
3. Prediction of prostate cancer to urethra distance by a pretreatment nomogram: urethral thermoprotection implication in cryoablation
- Author
-
Padilha, M M, Stephen Jones, J, Streator Smith, K, Zhou, M, Walker, E, and Magi-Galluzzi, C
- Published
- 2013
- Full Text
- View/download PDF
4. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer
- Author
-
Epstein, JI, Amin, MB, Fine, SW, Algaba, F, Aron, M, Baydar, DE, Beltran, AL, Brimo, F, Cheville, JC, Colecchia, M, Comperat, E, da Cunha, IW, Delprado, W, DeMarzo, AM, Giannico, GA, Gordetsky, JB, Guo, CC, Hansel, DE, Hirsch, MS, Huang, JT, Humphrey, PA, Jimenez, RE, Khani, F, Kong, QN, Kryvenko, ON, Kunju, LP, Lal, P, Latour, M, Lotan, T, Maclean, F, Magi-Galluzzi, C, Mehra, R, Menon, S, Miyamoto, H, Montironi, R, Netto, GJ, Nguyen, JK, Osunkoya, AO, Parwani, A, Robinson, BD, Rubin, MA, Shah, RB, So, JS, Takahashi, H, Tavora, F, Tretiakova, MS, True, L, Wobker, SE, Yang, XMJ, Zhou, M, Zynger, DL, and Trpkov, K
- Abstract
Context.-Controversies and uncertainty persist in prostate cancer grading. prostate cancer grading. Objective.-To update grading recommendations Data Sources.-Critical review of the literature along with pathology and clinician surveys. Conclusions.-Percent Gleason pattern 4 (%GP4) is as follows: (1) report %GP4 in needle biopsy with Grade Groups (GrGp) 2 and 3, and in needle biopsy on other parts (jars) of lower grade in cases with at least 1 part showing Gleason score (GS) 4 + 4 = 8; and (2) report %GP4: less than 5% or less than 10% and 10% increments thereafter. Tertiary grade patterns are as follows: (1) replace "tertiary grade pattern'' in radical prostatectomy (RP) with "minor tertiary pattern 5 (TP5),'' and only use in RP with GrGp 2 or 3 with less than 5% Gleason pattern 5; and (2) minor TP5 is noted along with the GS, with the GrGp based on the GS. Global score and magnetic resonance imaging (MRI)targeted biopsies are as follows: (1) when multiple undesignated cores are taken from a single MRI-targeted lesion, an overall grade for that lesion is given as if all the involved cores were one long core; and (2) if providing a global score, when different scores are found in the standard and the MRI-targeted biopsy, give a single global score (factoring both the systematic standard and the MRI-targeted positive cores). Grade Groups are as follows: (1) Grade Groups (GrGp) is the terminology adopted by major world organizations; and (2) retain GS 3 + 5 = 8 in GrGp 4. Cribriform carcinoma is as follows: (1) report the presence or absence of cribriform glands in biopsy and RP with Gleason pattern 4 carcinoma. Intraductal carcinoma (IDCP) is as follows: (1) report IDC-P in biopsy and RP; (2) use criteria based on dense cribriform glands (>50% of the gland is composed of epithelium relative to luminal spaces) and/or solid nests and/or marked pleomorphism/necrosis; (3) it is not necessary to perform basal cell immunostains on biopsy and RP to identify IDC-P if the results would not change the overall (highest) GS/GrGp part per case; (4) do not include IDC-P in determining the final GS/GrGp on biopsy and/or RP; and (5) "atypical intraductal proliferation (AIP)'' is preferred for an intraductal proliferation of prostatic secretory cells which shows a greater degree of architectural complexity and/or cytological atypia than typical high-grade prostatic intraepithelial neoplasia, yet falling short of the strict diagnostic threshold for IDC-P. Molecular testing is as follows: (1) Ki67 is not ready for routine clinical use; (2) additional studies of active surveillance cohorts are needed to establish the utility of PTEN in this setting; and (3) dedicated studies of RNA-based assays in active surveillance populations are needed to substantiate the utility of these expensive tests in this setting. Artificial intelligence and novel grading schema are as follows: (1) incorporating reactive stromal grade, percent GP4, minor tertiary GP5, and cribriform/intraductal carcinoma are not ready for adoption in current practice.
- Published
- 2021
5. Parasagittal biopsies are more important as part of an initial biopsy strategy than as part of a repeat biopsy strategy: observations from a unique population
- Author
-
Patel, A R, Jones, J S, Zhou, M, Schoenfield, L, and Magi-Galluzzi, C
- Published
- 2007
- Full Text
- View/download PDF
6. Mismatch Repair Gene Expression In Testicular Germ Cell Tumors And Retroperitoneal Lymph Node Metastasis
- Author
-
Youssef, M, primary, Rodriguez Pena, M, additional, Canete-Portillo, S, additional, Al Diffalha, S, additional, and Magi-Galluzzi, C, additional
- Published
- 2020
- Full Text
- View/download PDF
7. Discontinuous Involvement of Spermatic Cord Soft Tissue in Testicular Germ Cell Tumors: A Multi-Institution Experience
- Author
-
Ali, A, primary, So, J, additional, Khani, F, additional, Kvetoslava, M, additional, Miyamoto, H, additional, Osunkoya, A, additional, Rodriguez Pena, M, additional, Magi-Galluzzi, C, additional, Raspollini, M R, additional, Scarfo, F, additional, and Zynger, D L, additional
- Published
- 2020
- Full Text
- View/download PDF
8. Vascular Pattern and Density in Clear Cell vs Clear Cell Papillary Renal Cell Carcinoma
- Author
-
Canete-Portillo, S, primary, Rodriguez Pena, M, additional, Wang, D, additional, Netto, G J, additional, Magi-Galluzzi, C, additional, and Sanchez, D F, additional
- Published
- 2020
- Full Text
- View/download PDF
9. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
- Author
-
Epstein JI(1), Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Grading Committee.Al-Hussain T, Algaba F, Aron M, Berman D, Berney D, Brimo F, Cao D, Cheville J, Clouston D, Colecchia M, Comperat E, da Cunha IW, De Marzo A, Ertoy D, Fine S, Foster C, Grignon D, Gupta N, Gupta R, Kench J, Kristiansen G, Kunju L, Leite KR, Loda M, Lopez-Beltran A, Lotan T, Lucia M, Magi-Galluzzi C, Montironi R, McKenney J, Merrimen J, Netto G, Orozco R, Paner G, Parwani A, Pizov G, Reuter V, Ro J, Samaratunga H, Schultz L, Shanks J, Sesterhenn I, Shen S, Simko J, Suzigan S, Suryavanshi M, Tan PH, Takahashi H, Tomlins S, Trpkov K, Troncoso P, True L, Tsuzuki T, van der Kwast T, Varma M, Warren A, Wheeler T, Yang X, Zhou M, Kantoff P, Eisenberger M, Stadler W, Andriole G, Klein E, Benson M, Montorsi F, Crawford D, Loeb S, Catto J, Schaeffer E, Nacey JN, DeWeese T, Sandler H, Zietman A, Pollack A, Rodrigues G, Epstein, JI(1), Egevad, L, Amin, Mb, Delahunt, B, Srigley, Jr, Humphrey, Pa, Grading Committee., Al-Hussain T, Algaba, F, Aron, M, Berman, D, Berney, D, Brimo, F, Cao, D, Cheville, J, Clouston, D, Colecchia, M, Comperat, E, da Cunha, Iw, De Marzo, A, Ertoy, D, Fine, S, Foster, C, Grignon, D, Gupta, N, Gupta, R, Kench, J, Kristiansen, G, Kunju, L, Leite, Kr, Loda, M, Lopez-Beltran, A, Lotan, T, Lucia, M, Magi-Galluzzi, C, Montironi, R, Mckenney, J, Merrimen, J, Netto, G, Orozco, R, Paner, G, Parwani, A, Pizov, G, Reuter, V, Ro, J, Samaratunga, H, Schultz, L, Shanks, J, Sesterhenn, I, Shen, S, Simko, J, Suzigan, S, Suryavanshi, M, Tan, Ph, Takahashi, H, Tomlins, S, Trpkov, K, Troncoso, P, True, L, Tsuzuki, T, van der Kwast, T, Varma, M, Warren, A, Wheeler, T, Yang, X, Zhou, M, Kantoff, P, Eisenberger, M, Stadler, W, Andriole, G, Klein, E, Benson, M, Montorsi, F, Crawford, D, Loeb, S, Catto, J, Schaeffer, E, Nacey, Jn, Deweese, T, Sandler, H, Zietman, A, Pollack, A, and Rodrigues, G
- Subjects
Gleason grading system ,Pathology ,medicine.medical_specialty ,Neoplasm Grading ,business.industry ,Prostatectomy ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,medicine.disease ,Gleason Score 6 ,Pathology and Forensic Medicine ,PI-RADS ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Medicine ,Mucinous carcinoma ,Surgery ,Anatomy ,business ,Grading (education) - Abstract
In November, 2014, 65 prostate cancer pathology experts, along with 17 clinicians including urologists, radiation oncologists, and medical oncologists from 19 different countries gathered in a consensus conference to update the grading of prostate cancer, last revised in 2005. The major conclusions were: (1) Cribriform glands should be assigned a Gleason pattern 4, regardless of morphology; (2) Glomeruloid glands should be assigned a Gleason pattern 4, regardless of morphology; (3) Grading of mucinous carcinoma of the prostate should be based on its underlying growth pattern rather than grading them all as pattern 4; and (4) Intraductal carcinoma of the prostate without invasive carcinoma should not be assigned a Gleason grade and a comment as to its invariable association with aggressive prostate cancer should be made. Regarding morphologies of Gleason patterns, there was clear consensus on: (1) Gleason pattern 4 includes cribriform, fused, and poorly formed glands; (2) The term hypernephromatoid cancer should not be used; (3) For a diagnosis of Gleason pattern 4, it needs to be seen at 10x lens magnification; (4) Occasional/seemingly poorly formed or fused glands between well-formed glands is insufficient for a diagnosis of pattern 4; (5) In cases with borderline morphology between Gleason pattern 3 and pattern 4 and crush artifacts, the lower grade should be favored; (6) Branched glands are allowed in Gleason pattern 3; (7) Small solid cylinders represent Gleason pattern 5; (8) Solid medium to large nests with rosette-like spaces should be considered to represent Gleason pattern 5; and (9) Presence of unequivocal comedonecrosis, even if focal is indicative of Gleason pattern 5. It was recognized by both pathologists and clinicians that despite the above changes, there were deficiencies with the Gleason system. The Gleason grading system ranges from 2 to 10, yet 6 is the lowest score currently assigned. When patients are told that they have a Gleason score 6 out of 10, it implies that their prognosis is intermediate and contributes to their fear of having a more aggressive cancer. Also, in the literature and for therapeutic purposes, various scores have been incorrectly grouped together with the assumption that they have a similar prognosis. For example, many classification systems consider Gleason score 7 as a single score without distinguishing 3+4 versus 4+3, despite studies showing significantly worse prognosis for the latter. The basis for a new grading system was proposed in 2013 by one of the authors (J.I.E.) based on data from Johns Hopkins Hospital resulting in 5 prognostically distinct Grade Groups. This new system was validated in a multi-institutional study of over 20,000 radical prostatectomy specimens, over 16,000 needle biopsy specimens, and over 5,000 biopsies followed by radiation therapy. There was broad (90%) consensus for the adoption of this new prostate cancer Grading system in the 2014 consensus conference based on: (1) the new classification provided more accurate stratification of tumors than the current system; (2) the classification simplified the number of grading categories from Gleason scores 2 to 10, with even more permutations based on different pattern combinations, to Grade Groups 1 to 5; (3) the lowest grade is 1 not 6 as in Gleason, with the potential to reduce overtreatment of indolent cancer; and (4) the current modified Gleason grading, which forms the basis for the new grade groups, bears little resemblance to the original Gleason system. The new grades would, for the foreseeable future, be used in conjunction with the Gleason system [ie. Gleason score 3+3=6 (Grade Group 1)]. The new grading system and the terminology Grade Groups 1-5 have also been accepted by the World Health Organization for the 2016 edition of Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs.
- Published
- 2016
10. Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
- Author
-
Shepard, D. R., Dreicer, R., Garcia, J., Elson, P., Magi-Galluzzi, C., Raghavan, D., Stephenson, A.J., and Klein, E.A.
- Published
- 2009
11. Impact of Cribriform Pattern 4 and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy
- Author
-
Tom, M.C., primary, Nguyen, J.K., additional, Lucianò, R., additional, Mian, O.Y., additional, Stephans, K.L., additional, Ciezki, J.P., additional, Smile, T., additional, Wei, W., additional, McKenney, J., additional, Magi-Galluzzi, C., additional, and Tendulkar, R.D., additional
- Published
- 2019
- Full Text
- View/download PDF
12. Tumor Gene Expression Profiling in Prostate Cancer (PCa) Identifies Molecular Taxonomies Associated with Node Positivity and Quantitative Imaging Features on Multiparametric MRI (mpMRI)
- Author
-
Sittenfeld, S.M.C., primary, Williamson, D., additional, Tendulkar, R.D., additional, Stephans, K.L., additional, Ciezki, J.P., additional, Hwang, T.H., additional, Reddy, C.A., additional, McKenney, J., additional, Magi-Galluzzi, C., additional, Fareed, K., additional, Berglund, R., additional, Stephenson, A.J., additional, Klein, E.A., additional, Purysko, A., additional, and Mian, O.Y., additional
- Published
- 2018
- Full Text
- View/download PDF
13. Reporting and Staging of Testicular Germ Cell Tumors The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations
- Author
-
Verrill, C, Yilmaz, A, Srigley, JR, Amin, MB, Comperat, E, Egevad, L, Ulbright, TM, Tickoo, SK, Berney, DM, Epstein, JI, Delahunt, B, Magi-Galluzzi, C, Algaba, F, Oliva, E, Montironi, R, Young, RH, Idrees, MT, Williamson, SR, Zhou, M, Humphrey, PA, Lopez-Beltran, A, Perry-Keene, J, and Members Int Soc Urological
- Subjects
testicular germ cell tumors ,reporting and staging ,ISUP conference recommendations - Abstract
The International Society of Urological Pathology held a conference devoted to issues in testicular and penile pathology in Boston in March 2015, which included a presentation and discussion led by the testis microscopic features working group. This conference focused on controversies related to staging and reporting of testicular tumors and was preceded by an online survey of the International Society of Urological Pathology members. The survey results were used to initiate discussions, but decisions were made by expert consensus rather than voting. A number of recommendations emerged from the conference, including that lymphovascular invasion (LVI) should always be reported and no distinction need be made between lymphatic or blood invasion. If LVI is equivocal, then it should be regarded as negative to avoid triggering unnecessary therapy. LVI in the spermatic cord is considered as category pT2, not pT3, unless future studies provide contrary evidence. At the time of gross dissection, a block should be taken just superior to the epididymis to define the base of the spermatic cord, and direct invasion of tumor in this block indicates a category of pT3. Pagetoid involvement of the rete testis epithelium must be distinguished from rete testis stromal invasion, with only the latter being prognostically useful. Percentages of different tumor elements in mixed germ cell tumors should be reported. Although consensus was reached on many issues, there are still areas of practice that need further evidence on which to base firm recommendations.
- Published
- 2017
14. Molecular Profiling of Small Cell Bladder Cancer Reveals Gene Expression Determinants of an Aggressive Phenotype
- Author
-
Grivas, P., primary, Koshkin, V.S., additional, Pettiford, J., additional, Atkins, L., additional, Elson, P., additional, Reynolds, J., additional, Magi-Galluzzi, C., additional, McKenney, J., additional, Isse, K., additional, Saunders, L.R., additional, Hu, M., additional, Fergany, A.F., additional, Haber, G.P., additional, Garcia, J.A., additional, Rini, B., additional, Stephenson, A.J., additional, Tendulkar, R.D., additional, Abazeed, M., additional, and Mian, O.Y., additional
- Published
- 2017
- Full Text
- View/download PDF
15. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease
- Author
-
Magi-Galluzzi, C., Evans, A.J., Delahunt, B., Epstein, J.I., Griffiths, D.F., Kwast, T.H. van der, Montironi, R., Wheeler, T.M., Srigley, J.R., Egevad, L.L., Humphrey, P.A., and Hulsbergen-van de Kaa, C.A.
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Internationality ,Lymphovascular invasion ,medicine.medical_treatment ,Urinary Bladder ,Adenocarcinoma ,Specimen Handling ,Pathology and Forensic Medicine ,Surgical pathology ,Prostate cancer ,Translational research [ONCOL 3] ,medicine ,Humans ,Neoplasm Invasiveness ,Stage (cooking) ,Societies, Medical ,Neoplasm Staging ,Prostatectomy ,Clinical pathology ,business.industry ,Prostatic Neoplasms ,Anatomical pathology ,Prognosis ,medicine.disease ,Neck of urinary bladder ,Lymphatic Metastasis ,Lymph Nodes ,business ,Boston - Abstract
Contains fulltext : 97055.pdf (Publisher’s version ) (Closed access) The International Society of Urological Pathology Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens in Boston made recommendations regarding the standardization of pathology reporting of radical prostatectomy specimens. Issues relating to extraprostatic extension (pT3a disease), bladder neck invasion, lymphovascular invasion and the definition of pT4 were coordinated by working group 3. It was agreed that prostate cancer can be categorized as pT3a in the absence of adipose tissue involvement when cancer bulges beyond the contour of the gland or beyond the condensed smooth muscle of the prostate at posterior and posterolateral sites. Extraprostatic extension can also be identified anteriorly. It was agreed that the location of extraprostatic extension should be reported. Although there was consensus that the amount of extraprostatic extension should be quantitated, there was no agreement as to which method of quantitation should be employed. There was overwhelming consensus that microscopic urinary bladder neck invasion by carcinoma should be reported as stage pT3a and that lymphovascular invasion by carcinoma should be reported. It is recommended that these elements are considered in the development of practice guidelines and in the daily practice of urological surgical pathology. 01 januari 2011
- Published
- 2011
16. [Renal tumors: The International Society of Urologic Pathology (ISUP) 2012 consensus conference recommendations]
- Author
-
Rioux Leclercq, N, Ferran, A, Mahul, A, Argani, P, Billis, A, Bonsib, S, Cheng, L, Cheville, J, Eble, J, Egevad, L, Epstein, J, Grignon, D, Hes, O, Humphrey, P, Magi Galluzzi, C, Martignoni, Guido, Mckenney, J, Merino, M, Moch, H, Montironi, R, Netto, G, Reuter, V, Samaratunga, H, Shen, S, Srigley, J, Tamboli, P, Tan, Ph, Tickoo, S, Trpkov, K, Zhou, M, Delahunt, B, Comperat, E., University of Zurich, and Comperat, Eva
- Subjects
Adult ,Recommandations ,610 Medicine & health ,Conférence de consensus ,Recommendations ,Translocation, Genetic ,Diagnosis, Differential ,Neoplastic Syndromes, Hereditary ,10049 Institute of Pathology and Molecular Pathology ,Biomarkers, Tumor ,Humans ,Neoplasm Metastasis ,Cancer du rein ,Leiomyoma ,Carcinoma ,Sarcoma ,Kidney Diseases, Cystic ,Prognosis ,Kidney Neoplasms ,Neoplasm Proteins ,2734 Pathology and Forensic Medicine ,Renal cancer ,Cancer du rein, Conférence de consensus, Consensus conference, ISUP, Recommandations, Recommendations, Renal cancer ,ISUP ,Neoplasm Grading ,Consensus conference - Abstract
During the last 30 years many advances have been made in kidney tumor pathology. In 1981, 9 entities were recognized in the WHO Classification. In the latest classification of 2004, 50 different types have been recognized. Additional tumor entities have been described since and a wide variety of prognostic parameters have been investigated with variable success; however, much attention has centered upon the importance of features relating to both stage and grade. The International Society of Urological Pathology (ISUP) recommends after consensus conferences the development of reporting guidelines, which have been adopted worldwide ISUP undertook to review all aspects of the pathology of adult renal malignancy through an international consensus conference to be held in 2012. As in the past, participation in this consensus conference was restricted to acknowledged experts in the field.
- Published
- 2014
17. 730 Decipher genomic classifier measured on prostate biopsy predicts 10 year metastasis risk
- Author
-
Klein, E., primary, Haddad, Z, additional, Yousefi, K., additional, Lam, L., additional, Wang, Q., additional, Choeurng, V., additional, Palmer-Aronsten, B., additional, Buerki, C., additional, Davicioni, E., additional, Li, J., additional, Kattan, M.W., additional, Stephenson, A.J., additional, and Magi-Galluzzi, C., additional
- Published
- 2016
- Full Text
- View/download PDF
18. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters
- Author
-
Delahunt, B., Cheville, J.C., Martignoni, G., Humphrey, P.A., Magi-Galluzzi, C., McKenney, J., Egevad, L., Algaba, F., Moch, H., Grignon, D.J., Montironi, R., Srigley, J.R., and Hulsbergen-van de Kaa, C.A.
- Subjects
Translational research [ONCOL 3] ,urologic and male genital diseases - Abstract
Item does not contain fulltext The International Society of Urological Pathology 2012 Consensus Conference made recommendations regarding classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. Issues relating to prognostic factors were coordinated by a workgroup who identified tumor morphotype, sarcomatoid/rhabdoid differentiation, tumor necrosis, grading, and microvascular invasion as potential prognostic parameters. There was consensus that the main morphotypes of renal cell carcinoma (RCC) were of prognostic significance, that subtyping of papillary RCC (types 1 and 2) provided additional prognostic information, and that clear cell tubulopapillary RCC was associated with a more favorable outcome. For tumors showing sarcomatoid or rhabdoid differentiation, there was consensus that a minimum proportion of tumor was not required for diagnostic purposes. It was also agreed upon that the underlying subtype of carcinoma should be reported. For sarcomatoid carcinoma, it was further agreed upon that if the underlying carcinoma subtype was absent the tumor should be classified as a grade 4 unclassified carcinoma with a sarcomatoid component. Tumor necrosis was considered to have prognostic significance, with assessment based on macroscopic and microscopic examination of the tumor. It was recommended that for clear cell RCC the amount of necrosis should be quantified. There was consensus that nucleolar prominence defined grades 1 to 3 of clear cell and papillary RCCs, whereas extreme nuclear pleomorphism or sarcomatoid and/or rhabdoid differentiation defined grade 4 tumors. It was agreed upon that chromophobe RCC should not be graded. There was consensus that microvascular invasion should not be included as a staging criterion for RCC.
- Published
- 2013
19. 430 Molecular and clinical characterization of 1,577 primary prostate cancers reveal novel clinical and biological insights into subtypes
- Author
-
Karnes, J., primary, Tomlins, S., additional, Alshalalfa, M., additional, Davicioni, E., additional, Erho, N., additional, Yousefi, K., additional, Zhao, S., additional, Haddad, Z., additional, Den, R., additional, Dicker, A., additional, Trock, B., additional, Demarzo, A., additional, Ross, A., additional, Schaeffer, E., additional, Klein, E., additional, Magi-Galluzzi, C., additional, Jenkins, R., additional, and Feng, F., additional
- Published
- 2015
- Full Text
- View/download PDF
20. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis
- Author
-
Magi-Galluzzi C., Mishra R., Fiorentino M., Montironi R., Yao H., Capodieci P., Wishnow K., Kaplan I., Stork P. J. S., Loda M., Magi-Galluzzi C., Mishra R., Fiorentino M., Montironi R., Yao H., Capodieci P., Wishnow K., Kaplan I., Stork P.J.S., and Loda M.
- Subjects
Male ,Mitogen-Activated Protein Kinase 3 ,Transcription, Genetic ,JNK Mitogen-Activated Protein Kinases ,Prostate ,Prostatic Hyperplasia ,Gene Expression ,Prostatic Neoplasms ,Apoptosis ,Cell Cycle Proteins ,Dual Specificity Phosphatase 1 ,Immunohistochemistry ,Polymerase Chain Reaction ,Immediate-Early Proteins ,MKP-1, prostate cancer ,Protein Phosphatase 1 ,Calcium-Calmodulin-Dependent Protein Kinases ,Phosphoprotein Phosphatases ,Humans ,RNA, Messenger ,Mitogen-Activated Protein Kinases ,Protein Tyrosine Phosphatases ,Cell Division ,In Situ Hybridization - Abstract
Several oncogenes involved in prostate carcinogenesis activate mitogen- activated protein (MAP) kinases, which can relay both proliferative (via extracellular regulated kinases (ERK)) and apoptotic signals (via jun N- terminal protein kinases (JNK)) to the nucleus. Mitogen-activated protein kinase phosphatase 1 (MKP-1) is induced by several oncogenes in the ras- dependent pathway and can inactivate both MAP kinase pathways. The role of MKP-1 in proliferation and apoptosis is, however, still controversial. A series of 51 prostate cancers, including a subset (n = 13) that had been previously treated by androgen ablation, was used to examine whether MKP-1 mRNA and protein expression correlated with that of ERK-1, JNK-1, bcl-2, which confers resistance to apoptosis, and apoptotic index measured by in situ end-labeling of fragmented DNA. In a subset of tumors, MKP-1 expression was assessed by semiquantitative RT-PCR and was compared with both ERK-1 and JNK-1 enzymatic activity. In cases not treated by endrogen ablation, MKP-1 was overexpressed in the preinvasive stage of prostate cancer, but its expression decreased with higher histologic grade and advanced disease stage. There was coexpression of MKP-1, ERK-1, and JNK-1 proteins. In addition, MKP- 1 expression was inversely correlated to JNK-1 but not to ERK-1 enzymatic activity. Finally, MKP-1 and bcl-2 were inversely related to apoptotic indices. In cases treated by total androgen ablation, MKP-1 and bcl-2 were both down-regulated, whereas JNK-1 was up-regulated. Subpopulations of cells that did not undergo apoptosis maintained expression of both MKP-1 and bcl- 2. These results suggest that MKP-1 overexpression is associated with the early phases of neoplastic transformation in prostate tissue. The enzymatic data on MKP-1 kinase substrates and the inverse correlation between MKP-1 and parameters of programmed cell death support the hypothesis that MKP-1 inhibits apoptosis in human prostate tumors, perhaps through the JNK pathway.
- Published
- 1997
21. Quantitative gene expression in primary and highest Gleason pattern cancer specimens identifies genes associated with clinical recurrence and prostate cancer–specific survival after radical prostatectomy.
- Author
-
Klein, E. A., primary, Falzarano, S. M., additional, Maddala, T., additional, Lee, M., additional, Pelham, R. J., additional, Novotny, W. F., additional, Shak, S., additional, and Magi-Galluzzi, C., additional
- Published
- 2011
- Full Text
- View/download PDF
22. Use of TMPRSS2-ERGgene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy.
- Author
-
Falzarano, S. M., primary, Magi-Galluzzi, C., additional, Novotny, W. F., additional, Maddala, T., additional, Cherbavaz, D. B., additional, Millward, C., additional, and Klein, E. A., additional
- Published
- 2011
- Full Text
- View/download PDF
23. Use of quantitative gene expression in primary and highest Gleason pattern cancers to identify genes associated with clinical recurrence after radical prostatectomy.
- Author
-
Klein, E. A., primary, Falzarano, S. M., additional, Maddala, T., additional, Millward, C., additional, Novotny, W. F., additional, Pelham, R. J., additional, and Magi-Galluzzi, C., additional
- Published
- 2011
- Full Text
- View/download PDF
24. Use of TMPRSS2-ERG gene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy.
- Author
-
Klein, E. A., primary, Falzarano, S. M., additional, Maddala, T., additional, Cherbavaz, D., additional, Novotny, W. F., additional, Millward, C., additional, and Magi-Galluzzi, C., additional
- Published
- 2011
- Full Text
- View/download PDF
25. The Role of Percent Positive Cores in the Biopsy Specimen for Predicting Biochemical Outcome following External Beam Radiotherapy or I-125 Brachytherapy
- Author
-
Martires, K.J., primary, Tendulkar, R.D., additional, Reddy, C.A., additional, Ciezki, J.C., additional, Jones, J.S., additional, Klein, E.A., additional, Patel, A.R., additional, Chehade, N., additional, Magi-Galluzzi, C., additional, and Stephans, K.L., additional
- Published
- 2010
- Full Text
- View/download PDF
26. Open vs. Laparoscopic Prostatectomy: Implications for Adjuvant Radiotherapy
- Author
-
Tendulkar, R.D., primary, Stephans, K.L., additional, Reddy, C.A., additional, Reuther, A., additional, Magi-Galluzzi, C., additional, Zhou, M., additional, and Klein, E.A., additional
- Published
- 2009
- Full Text
- View/download PDF
27. Neoadjuvant GM-CSF and thalidomide in men with high-risk prostate carcinoma undergoing radical prostatectomy
- Author
-
Garcia, J. A., primary, Magi-Galluzzi, C., additional, Rothaermel, J., additional, Elson, P., additional, Zhou, M., additional, Klein, E., additional, and Dreicer, R., additional
- Published
- 2006
- Full Text
- View/download PDF
28. Threshold for diagnosing prostate cancer over time
- Author
-
Magi-Galluzzi, C, primary
- Published
- 2003
- Full Text
- View/download PDF
29. Apoptosis in Prostatic Adenocarcinoma following Complete Androgen Ablation
- Author
-
Montironi, R., primary, Pomante, R., additional, Diamanti, L., additional, and Magi-Galluzzi, C., additional
- Published
- 1998
- Full Text
- View/download PDF
30. Molecular Events in the Early Phases of Prostate Carcinogenesis
- Author
-
Magi-Galluzzi, C., primary and Loda, M., additional
- Published
- 1996
- Full Text
- View/download PDF
31. Apoptotic Bodies in Prostatic Intraepithelial Neoplasia and Prostatic Adenocarcinoma Following Total Androgen Ablation
- Author
-
Monfironi, R., primary, Magi-Galluzzi, C., additional, and Fabris, G., additional
- Published
- 1995
- Full Text
- View/download PDF
32. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
- Author
-
Montironi, R, primary, Magi-Galluzzi, C, additional, Muzzonigro, G, additional, Prete, E, additional, Polito, M, additional, and Fabris, G, additional
- Published
- 1994
- Full Text
- View/download PDF
33. Prostatic Invasive Adenocarcinoma
- Author
-
Magi Galluzzi, C., primary, Montironi, R., additional, Giannulis, I., additional, Diamanti, L., additional, Scarpelli, M., additional, Muzzonigro, G., additional, and Polito, M., additional
- Published
- 1993
- Full Text
- View/download PDF
34. Computed cell cycle and DNA histogram analyses in image cytometry in breast cancer.
- Author
-
Montironi, R, primary, Diamanti, L, additional, Santinelli, A, additional, Magi Galluzzi, C, additional, Scarpelli, M, additional, Giannulis, I, additional, and Mangili, F, additional
- Published
- 1993
- Full Text
- View/download PDF
35. Prostatic Intra-epithelial Neoplasia
- Author
-
Montironi, R., primary, Magi Galluzzi, C., additional, Diamanti, L., additional, Taborro, R., additional, Scarpelli, M., additional, and Pisani, E., additional
- Published
- 1993
- Full Text
- View/download PDF
36. Quantitative analysis of quadriceps muscle biopsy in systemic sclerosis
- Author
-
Scarpelli, M., primary, Montironi, R., additional, Tulli, D., additional, Sisti, S., additional, Matera, G., additional, Magi Galluzzi, C., additional, and Collan, Y., additional
- Published
- 1992
- Full Text
- View/download PDF
37. Differential expression of melanocytic markers in myoid, lipomatous, and vascular components of renal angiomyolipomas.
- Author
-
Roma AA, Magi-Galluzzi C, and Zhou M
- Published
- 2007
- Full Text
- View/download PDF
38. Mitogen-activated protein kinases and apoptosis in PIN.
- Author
-
Magi-Galluzzi, Cristina, Montironi, R., Cangi, M. Giulia, Wishnow, Kenneth, Loda, Massimo, Magi-Galluzzi, C, Cangi, M G, Wishnow, K, and Loda, M
- Abstract
Mitogen-activated protein (MAP) kinases are key elements of the signalling systems needed to transduce different extracellular messages into cellular responses. At least three parallel MAP kinase pathways have been identified: one, stimulated by serum and growth factors to activate extracellular signal-regulated protein kinases (ERKs) by dual tyrosine and threonine phosphorylation, triggers cell proliferation or differentiation; the other two, induced by a variety of cellular stresses to activate c-jun N-terminal kinases (JNKs) and reactivating kinase (p38/RK), result in growth arrest and induction of apoptosis. Mitogen-activated protein kinase phosphatases (MKPs) inactivate MAP kinases through dephosphorylation and, thus, can modulate the MAP kinase pathways. Expression of JNK-1, ERK-1, p38/RK and MKP-1 proteins was investigated by immunohistochemistry and expression of MKP-1 mRNA by in situ hybridisation in 50 cases of high-grade prostatic intraepithelial neoplasia (PIN), thought to represent the precursor of prostate cancer. The frequency of apoptotic cells was also determined in these cases. Overexpression of the three MAP kinases and MKP-1 mRNA was found in all cases of high-grade PIN compared with normal prostate. Immunoreactivity for MKP-1 protein was found to be as intense as in normal glands in 30% and weaker in 56% of the PIN cases. Fourteen per cent of PIN cases did not stain with MKP-1 antibody. The proportion of apoptosis was significantly higher (P < 0.008) in PIN lesions that did not express MKP-1 protein than in those that did. These results are consistent with our previous demonstration of preferential inhibition of the apoptosis-related kinases by MKP-1 and further support the contention that MKP-1, even in PIN, may shift the balance existing between cell proliferation and death. When expressed, it may inhibiting those pathways that lead to apoptosis. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
39. Fumarát hydratáza deficientní karcinom z renálních buněk a jemu podobný karcinom z renálních buněk: Komparativní studie 23 geneticky testovaných případů,Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases
- Author
-
Pivovarčíková, K., Martínek, P., Trpkov, K., Reza Alaghehbandan, Magi-Galluzzi, C., Mundo, E. C., Berney, D., Suster, S., Gill, A., Rychlý, B., Michalová, K., Pitra, T., Hora, M., Michal, M., and Hes, O.
40. Novel biomarkers and genomic tests in prostate cancer: A critical analysis
- Author
-
Falzarano, S. M., Ferro, M., Bollito, E., Eric A Klein, Carrieri, G., and Magi-Galluzzi, C.
41. Erratum: A working group classification of focal prostate atrophy lesions (American Journal of Surgical Pathology (2006) 30 (1281-1291))
- Author
-
Marzo, A. M., Platz, E. A., Epstein, J. I., Ali, T., Billis, A., Chan, T. Y., Cheng, L., Datta, M., Egevad, L., Ertoy-Baydar, D., Xavier Farré, Fine, S. W., Iczkowski, K. A., Ittmann, M., Knudsen, B. S., Loda, M., Lopez-Beltran, A., Magi-Galluzzi, C., Mikuz, G., Montironi, R., Pikarsky, E., Pizov, G., Rubin, M. A., Samaratunga, H., Sebo, T., Sesterhenn, I. A., Shah, R. B., Signoretti, S., Simko, J., Thomas, G., Troncoso, P., Tsuzuki, T. T., Leenders, G. J., Yang, X. J., Zhou, M., Figg, W. D., Hoque, A., and Lucia, M. S.
42. A working group classification of focal prostate atrophy lesions. (vol 30, pg 1281, 2006)
- Author
-
Marzo, A. M., Platz, E. A., Epstein, J., Ali, T., Billis, A., Chan, T. Y., Cheng, L., Datta, M., Egevad, L., Ertoy-Baydar, D., Farree, X., Fine, S. W., Iczkowski, K. A., Ittmann, M., Knudsen, B. S., Loda, M., Lopez-Beltran, A., Magi-Galluzzi, C., Mikuz, G., Montironi, R., Pikarsky, E., Pizov, G., Rubin, M. A., Hemamali Samaratunga, Sebo, T., Sesterhenn, I. A., Shah, R. B., Signoretti, S., Simko, J., Thomas, G., Troncoso, P., Tsuzuki, T. T., Leenders, G. J., Yang, X. J., Zhou, M., Figg, W. D., Hoque, A., Lucia, M. S., and Pathology
43. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables
- Author
-
Alessandra Soriano, Moira Ragazzi, Maria Paola Bonasoni, Francesca Sanguedolce, Alessandra Bisagni, Alessandro Tafuni, Matteo Landriscina, Beatrice Melli, Giacomo Santandrea, Giuseppe Carrieri, Alberto Cavazza, Guido Giordano, Sofia Canete-Portillo, Luigi Cormio, Dario de Biase, Antonio De Leo, Stefania Croci, Daniel Abensur Athanazio, Eleonora Zanetti, Alcides Chaux, Cristina Magi-Galluzzi, Andrea Palicelli, Magda Zanelli, Carolina Castro Ruiz, Martina Bonacini, Daniel M. Berney, Jatin Gandhi, Stefano Ascani, Maurizio Zizzo, Palicelli A., Bonacini M., Croci S., Magi-Galluzzi C., Canete-Portillo S., Chaux A., Bisagni A., Zanetti E., De Biase D., Melli B., Sanguedolce F., Ragazzi M., Bonasoni M.P., Soriano A., Ascani S., Zizzo M., Ruiz C.C., De Leo A., Giordano G., Landriscina M., Carrieri G., Cormio L., Berney D.M., Athanazio D., Gandhi J., Cavazza A., Santandrea G., Tafuni A., and Zanelli M.
- Subjects
Oncology ,Male ,PD-L1 ,target-therapy ,medicine.medical_specialty ,QH301-705.5 ,Adenocarcinoma ,Cancer ,Checkpoint inhibitors ,Im-munotherapy ,Immunohistochemistry ,Prostate ,Target-therapy ,Antibodies, Neoplasm ,Pembrolizumab ,Review ,B7-H1 Antigen ,Prostate cancer ,Internal medicine ,Checkpoint inhibitor ,medicine ,Carcinoma ,Humans ,cancer ,Biology (General) ,prostate ,adenocarcinoma ,biology ,business.industry ,Prostatic Neoplasms ,General Medicine ,medicine.disease ,medicine.anatomical_structure ,biology.protein ,immunotherapy ,Antibody ,business ,checkpoint inhibitors ,Human - Abstract
Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different immunologically ‘‘hot’’ tumors. A phase II study revealed good therapeutic activity of pembrolizumab in selected prostatic carcinoma (PC)-patients. We performed a systematic literature review (PRISMA guidelines), which analyzes the immunohistochemical expression of PD-L1 in human PC samples and highlights the pre-analytical and interpretation variables. Interestingly, 29% acinar PCs, 7% ductal PCs, and 46% neuroendocrine carcinomas/tumors were PD-L1+ on immunohistochemistry. Different scoring methods or cut-off criteria were applied on variable specimen-types, evaluating tumors showing different clinic-pathologic features. The positivity rate of different PD-L1 antibody clones in tumor cells ranged from 3% (SP142) to 50% (ABM4E54), excluding the single case tested for RM-320. The most tested clone was E1L3N, followed by 22C3 (most used for pembrolizumab eligibility), SP263, SP142, and 28-8, which gave the positivity rates of 35%, 11–41% (depending on different scoring systems), 6%, 3%, and 15%, respectively. Other clones were tested in
- Published
- 2021
44. What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 2: Clinic–pathologic correlations
- Author
-
Sofia Canete-Portillo, Magda Zanelli, Giacomo Santandrea, Daniel M. Berney, Luigi Cormio, Guido Giordano, Cristina Magi-Galluzzi, Stefania Croci, Stefano Ascani, Alcides Chaux, Eleonora Zanetti, Loredana De Marco, Matteo Landriscina, Maria Carolina Gelli, Alessandra Bisagni, Maurizio Zizzo, Giuseppe Carrieri, Beatrice Melli, Jatin Gandhi, Alessandro Tafuni, Antonio De Leo, Martina Bonacini, Alessandra Soriano, Dario de Biase, Maria Paola Bonasoni, Francesca Sanguedolce, Andrea Palicelli, Carolina Castro Ruiz, Moira Ragazzi, Palicelli A., Bonacini M., Croci S., Magi-Galluzzi C., Canete-Portillo S., Chaux A., Bisagni A., Zanetti E., De Biase D., Melli B., Sanguedolce F., Zanelli M., Bonasoni M.P., De Marco L., Soriano A., Ascani S., Zizzo M., Ruiz C.C., De Leo A., Giordano G., Landriscina M., Carrieri G., Cormio L., Berney D.M., Gandhi J., Santandrea G., Gelli M.C., Tafuni A., and Ragazzi M.
- Subjects
Male ,Oncology ,PD-L1 ,medicine.medical_specialty ,QH301-705.5 ,Adenocarcinoma ,Cancer ,Checkpoint inhibitors ,Im-munotherapy ,Immunohistochemistry ,Prostate ,Target-therapy ,Ipilimumab ,Review ,B7-H1 Antigen ,Prostate cancer ,chemistry.chemical_compound ,Castration Resistance ,Checkpoint inhibitor ,Internal medicine ,Carcinoma ,Humans ,Medicine ,Degarelix ,Biology (General) ,Neoplasm Staging ,business.industry ,Prostatic Neoplasms ,Lymphatic Metastasi ,General Medicine ,medicine.disease ,Survival Analysis ,GVAX ,chemistry ,Lymphatic Metastasis ,Prostatic Neoplasm ,immunotherapy ,Neoplasm Grading ,Neoplasm Recurrence, Local ,business ,checkpoint inhibitors ,Human ,medicine.drug - Abstract
Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized.
- Published
- 2021
45. Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey
- Author
-
John C. Cheville, Dilek Ertoy Baydar, George J. Netto, Sara E. Wobker, Ming Zhou, Rafael E. Jimenez, Hiroyuki Takahashi, Fabio Tavora, Antonio Beltran, Donna E. Hansel, Rodolfo Montironi, Angelo M. DeMarzo, Christian P. Pavlovich, Michelle S. Hirsch, Fiona Maclean, Kiril Trpkov, L. Priya Kunju, Rohit Mehra, Rajal B. Shah, Ferran Algaba, Isabela Werneck da Cunha, Santosh Menon, Brian D. Robinson, Tony Costello, Jennifer B. Gordetsky, Warick Delprado, Peter A. Humphrey, Jeffrey S. So, Giovanna A. Giannico, Jiaoti Huang, Ximing J. Yang, Anil V. Parwani, Fadi Brimo, Mark A. Rubin, Lawrence D. True, Charles C. Guo, Hiroshi Miyamoto, Debra L. Zynger, Oleksandr N. Kryvenko, Samson W. Fine, Jane K. Nguyen, Mahul B. Amin, Tamara L. Lotan, Manju Aron, Maurizio Colecchia, Francesca Khani, Cristina Magi-Galluzzi, Jonathan I. Epstein, Adeboye O. Osunkoya, Max X. Kong, Eva Comperat, Mathieu Latour, Priti Lal, Maria S. Tretiakova, Fine, S. W., Trpkov, K., Amin, M. B., Algaba, F., Aron, M., Baydar, D. E., Beltran, A. L., Brimo, F., Cheville, J. C., Colecchia, M., Comperat, E., Costello, T., da Cunha, I. W., Delprado, W., Demarzo, A. M., Giannico, G. A., Gordetsky, J. B., Guo, C. C., Hansel, D. E., Hirsch, M. S., Huang, J., Humphrey, P. A., Jimenez, R. E., Khani, F., Kong, M. X., Kryvenko, O. N., Kunju, L. P., Lal, P., Latour, M., Lotan, T., Maclean, F., Magi-Galluzzi, C., Mehra, R., Menon, S., Miyamoto, H., Montironi, R., Netto, G. J., Nguyen, J. K., Osunkoya, A. O., Parwani, A., Pavlovich, C. P., Robinson, B. D., Rubin, M. A., Shah, R. B., So, J. S., Takahashi, H., Tavora, F., Tretiakova, M. S., True, L., Wobker, S. E., Yang, X. J., Zhou, M., Zynger, D. L., and Epstein, J. I.
- Subjects
Image-Guided Biopsy ,Male ,Pathology ,medicine.medical_specialty ,Urology ,030232 urology & nephrology ,Cribriform ,Disease ,Active surveillance ,Article ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Carcinoma ,Humans ,Medicine ,Practice Patterns, Physicians' ,610 Medicine & health ,Grading (tumors) ,medicine.diagnostic_test ,Descriptive statistics ,Practice patterns ,business.industry ,Genitourinary system ,Prostatic Neoplasms ,Magnetic resonance imaging ,medicine.disease ,Health Surveys ,Magnetic Resonance Imaging ,Grading ,Oncology ,030220 oncology & carcinogenesis ,Neoplasm Grading ,business ,MRI - Abstract
Purpose: To survey urologic clinicians regarding interpretation of and practice patterns in relation to emerging aspects of prostate cancer grading, including quantification of high-grade disease, cribriform/intraductal carcinoma, and impact of magnetic resonance imaging-targeted needle biopsy. Materials and methods: The Genitourinary Pathology Society distributed a survey to urology and urologic oncology-focused societies and hospital departments. Eight hundred and thirty four responses were collected and analyzed using descriptive statistics. Results: Eighty percent of survey participants use quantity of Gleason pattern 4 on needle biopsy for clinical decisions, less frequently with higher Grade Groups. Fifty percent interpret "tertiary" grade as a minor/< 5% component. Seventy percent of respondents would prefer per core grading as well as a global/overall score per set of biopsies, but 70% would consider highest Gleason score in any single core as the grade for management. Seventy five percent utilize Grade Group terminology in patient discussions. For 45%, cribriform pattern would affect management, while for 70% the presence of intraductal carcinoma would preclude active surveillance. Conclusion: This survey of practice patterns in relationship to prostate cancer grading highlights similarities and differences between contemporary pathology reporting and its clinical application. As utilization of Gleason pattern 4 quantification, minor tertiary pattern, cribriform/intraductal carcinoma, and the incorporation of magnetic resonance imaging-based strategies evolve, these findings may serve as a basis for more nuanced communication and guide research efforts involving pathologists and clinicians. (C) 2020 Elsevier Inc. All rights reserved.
- Published
- 2021
46. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer
- Author
-
Jeffrey S. So, Rajal B. Shah, Brian D. Robinson, John C. Cheville, Angelo M. DeMarzo, Francesca Khani, Charles C. Guo, Ximing J. Yang, Fiona Maclean, Maurizio Colecchia, Rodolfo Montironi, Dilek Ertoy Baydar, Sara E. Wobker, Manju Aron, Eva Compérat, Warick Delprado, Mark A. Rubin, Mathieu Latour, Antonio Beltran, Lawrence D. True, Mahul B. Amin, Oleksandr N. Kryvenko, Jiaoti Huang, Qingnuan Kong, Georges J Netto, Cristina Magi-Galluzzi, L. Priya Kunju, Rohit Mehra, Rafael E. Jimenez, Ferran Algaba, Giovanna A. Giannico, Anil V. Parwani, Isabela Werneck da Cunha, Kiril Trpkov, Fadi Brimo, Santosh Menon, Tamara L. Lotan, Jane K. Nguyen, Hiroyuki Takahashi, Jonathan I. Epstein, Adeboye O. Osunkoya, Peter A. Humphrey, Jennifer Gordetsky, Debra L. Zynger, Donna E. Hansel, Samson W. Fine, Maria S. Tretiakova, Fabio Tavora, Michelle S. Hirsch, Ming Zhou, Hiroshi Miyamoto, Priti Lal, Epstein, J. I., Amin, M. B., Fine, S. W., Algaba, F., Aron, M., Baydar, D. E., Beltran, A. L., Brimo, F., Cheville, J. C., Colecchia, M., Comperat, E., da Cunha, I. W., Delprado, W., Demarzo, A. M., Giannico, G. A., Gordetsky, J. B., Guo, C. C., Hansel, D. E., Hirsch, M. S., Huang, J., Humphrey, P. A., Jimenez, R. E., Khani, F., Kong, Q., Kryvenko, O. N., Kunju, L. P., Lal, P., Latour, M., Lotan, T., Maclean, F., Magi-Galluzzi, C., Mehra, R., Menon, S., Miyamoto, H., Montironi, R., Netto, G. J., Nguyen, J. K., Osunkoya, A. O., Parwani, A., Robinson, B. D., Rubin, M. A., Shah, R. B., So, J. S., Takahashi, H., Tavora, F., Tretiakova, M. S., True, L., Wobker, S. E., Yang, X. J., Zhou, M., Zynger, D. L., and Trpkov, K.
- Subjects
Image-Guided Biopsy ,Male ,Pathology ,medicine.medical_specialty ,Consensus ,030232 urology & nephrology ,MEDLINE ,Pathology and Forensic Medicine ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,White paper ,Predictive Value of Tests ,Biopsy ,medicine ,Biomarkers, Tumor ,Humans ,610 Medicine & health ,Grading (tumors) ,medicine.diagnostic_test ,Genitourinary system ,business.industry ,Biopsy, Needle ,Prostatic Neoplasms ,General Medicine ,medicine.disease ,Immunohistochemistry ,Magnetic Resonance Imaging ,Medical Laboratory Technology ,Molecular Diagnostic Techniques ,030220 oncology & carcinogenesis ,Predictive value of tests ,Neoplasm Grading ,business - Abstract
Context.— Controversies and uncertainty persist in prostate cancer grading. Objective.— To update grading recommendations. Data Sources.— Critical review of the literature along with pathology and clinician surveys. Conclusions.— Percent Gleason pattern 4 (%GP4) is as follows: (1) report %GP4 in needle biopsy with Grade Groups (GrGp) 2 and 3, and in needle biopsy on other parts (jars) of lower grade in cases with at least 1 part showing Gleason score (GS) 4 + 4 = 8; and (2) report %GP4: less than 5% or less than 10% and 10% increments thereafter. Tertiary grade patterns are as follows: (1) replace “tertiary grade pattern” in radical prostatectomy (RP) with “minor tertiary pattern 5 (TP5),” and only use in RP with GrGp 2 or 3 with less than 5% Gleason pattern 5; and (2) minor TP5 is noted along with the GS, with the GrGp based on the GS. Global score and magnetic resonance imaging (MRI)-targeted biopsies are as follows: (1) when multiple undesignated cores are taken from a single MRI-targeted lesion, an overall grade for that lesion is given as if all the involved cores were one long core; and (2) if providing a global score, when different scores are found in the standard and the MRI-targeted biopsy, give a single global score (factoring both the systematic standard and the MRI-targeted positive cores). Grade Groups are as follows: (1) Grade Groups (GrGp) is the terminology adopted by major world organizations; and (2) retain GS 3 + 5 = 8 in GrGp 4. Cribriform carcinoma is as follows: (1) report the presence or absence of cribriform glands in biopsy and RP with Gleason pattern 4 carcinoma. Intraductal carcinoma (IDC-P) is as follows: (1) report IDC-P in biopsy and RP; (2) use criteria based on dense cribriform glands (>50% of the gland is composed of epithelium relative to luminal spaces) and/or solid nests and/or marked pleomorphism/necrosis; (3) it is not necessary to perform basal cell immunostains on biopsy and RP to identify IDC-P if the results would not change the overall (highest) GS/GrGp part per case; (4) do not include IDC-P in determining the final GS/GrGp on biopsy and/or RP; and (5) “atypical intraductal proliferation (AIP)” is preferred for an intraductal proliferation of prostatic secretory cells which shows a greater degree of architectural complexity and/or cytological atypia than typical high-grade prostatic intraepithelial neoplasia, yet falling short of the strict diagnostic threshold for IDC-P. Molecular testing is as follows: (1) Ki67 is not ready for routine clinical use; (2) additional studies of active surveillance cohorts are needed to establish the utility of PTEN in this setting; and (3) dedicated studies of RNA-based assays in active surveillance populations are needed to substantiate the utility of these expensive tests in this setting. Artificial intelligence and novel grading schema are as follows: (1) incorporating reactive stromal grade, percent GP4, minor tertiary GP5, and cribriform/intraductal carcinoma are not ready for adoption in current practice.
- Published
- 2020
47. Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate A Survey of Genitourinary Subspecialists
- Author
-
Christopher G. Przybycin, Peter A. Humphrey, Manju Aron, Victor E. Reuter, Luciana Schultz, Mahul B. Amin, John C. Cheville, Theodorus van der Kwast, Lakshmi P. Kunju, Samson W. Fine, Maurizio Colecchia, David J. Grignon, Rohit Mehra, Gladell P. Paner, Rodolfo Montironi, Radhika Sekhri, Michelle S. Hirsch, Jonathan I. Epstein, Cristina Magi-Galluzzi, Ondrej Hes, George J. Netto, Jatin S. Gandhi, Adeboye O. Osunkoya, Deepika Sirohi, Charlotte F. Kweldam, Alexander S. Baras, Steven C. Smith, Oleksandr N. Kryvenko, Rajal B. Shah, Rafael E. Jimenez, Sean R. Williamson, James G. Kench, Brian D. Robinson, Fabio Tavora, Angelo M. DeMarzo, Naoto Kuroda, Ankur R. Sangoi, Kiril Trpkov, Jae Y. Ro, Santosh Menon, Donna E. Hansel, Seema Kaushal, Jesse K. McKenney, Internal Medicine, Gandhi, J. S., Smith, S. C., Paner, G. P., Mckenney, J. K., Sekhri, R., Osunkoya, A. O., Baras, A. S., Demarzo, A. M., Cheville, J. C., Jimenez, R. E., Trpkov, K., Colecchia, M, Ro, J. Y., Montironi, R., Menon, S., Hes, O., Williamson, S. R., Hirsch, M. S., Netto, G. J., Fine, S. W., Sirohi, D., Kaushal, S., Sangoi, A., Robinson, B. D., Kweldam, C. F., Humphrey, P. A., Hansel, D. E., Schultz, L., Magi-Galluzzi, C., Przybycin, C. G., Shah, R. B., Mehra, R., Kunju, L. P., Aron, M., Kryvenko, O. N., Kench, J. G., Kuroda, N., Tavora, F., van der Kwast, T., Grignon, D. J., Epstein, J. I., Reuter, V. E., and Amin, M. B.
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,medicine.medical_treatment ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Internal medicine ,Biopsy ,Biomarkers, Tumor ,Carcinoma ,Humans ,Medicine ,Clinical significance ,Practice Patterns, Physicians' ,skin and connective tissue diseases ,Contraindication ,medicine.diagnostic_test ,business.industry ,Genitourinary system ,Prostatectomy ,Prostatic Neoplasms ,Reproducibility of Results ,Cancer ,medicine.disease ,Immunohistochemistry ,Carcinoma, Ductal ,030104 developmental biology ,Health Care Surveys ,030220 oncology & carcinogenesis ,Predictive value of tests ,Health Resources ,Surgery ,Biopsy, Large-Core Needle ,Neoplasm Grading ,Anatomy ,business ,Specialization - Abstract
Intraductal carcinoma of the prostate (IDC-P) has been recently recognized by the World Health Organization classification of prostatic tumors as a distinct entity, most often occurring concurrently with invasive prostatic adenocarcinoma (PCa). Whether documented admixed with PCa or in its rare pure form, numerous studies associate this entity with clinical aggressiveness. Despite increasing clinical experience and requirement of IDC-P documentation in protocols for synoptic reporting, the specifics of its potential contribution to assessment of grade group (GG) and cancer quantitation of PCa in both needle biopsies (NBx) and radical prostatectomy (RP) specimens remain unclear. Moreover, there are no standard guidelines for incorporating basal cell marker immunohistochemistry (IHC) in the diagnosis of IDC-P, either alone or as part of a cocktail with AMACR/racemase. An online survey containing 26 questions regarding diagnosis, reporting practices, and IHC resource utilization, focusing on IDC-P, was undertaken by 42 genitourinary subspecialists from 9 countries. The degree of agreement or disagreement regarding approaches to individual questions was classified as significant majority (>75%), majority (51% to 75%), minority (26% to 50%) and significant minority (≤25%). IDC-P with or without invasive cancer is considered a contraindication for active surveillance by the significant majority (95%) of respondents, although a majority (66%) also agreed that the clinical significance/behavior of IDC-P on NBx or RP with PCa required further study. The majority do not upgrade PCa based on comedonecrosis seen only in the intraductal component in NBx (62%) or RP (69%) specimens. Similarly, recognizable IDC-P with GG1 PCa was not a factor in upgrading in NBx (78%) or RP (71%) specimens. The majority (60%) of respondents include readily recognizable IDC-P in assessment of linear extent of PCa at NBx. A significant majority (78%) would use IHC to confirm or exclude intraductal carcinoma if other biopsies showed no PCa, while 60% would use it to confirm IDC-P with invasive PCa in NBx if it would change the overall GG assignment. Nearly half (48%, a minority) would use IHC to confirm IDC-P for accurate Gleason pattern 4 quantitation. A majority (57%) report the percentage of IDC-P when present, in RP specimens. When obvious Gleason pattern 4 or 5 PCa is present in RP or NBx, IHC is rarely to almost never used to confirm the presence of IDC-P by the significant majority (88% and 90%, respectively). Most genitourinary pathologists consider IDC-P to be an adverse prognostic feature independent of the PCa grade, although recommendations for standardization are needed to guide reporting of IDC-P vis a vis tumor quantitation and final GG assessment. The use of IHC varies widely and is performed for a multitude of indications, although it is used most frequently in scenarios where confirmation of IDC-P would impact the GG assigned. Further study and best practices recommendations are needed to provide guidance with regards to the most appropriate indications for IHC use in scenarios regarding IDC-P.
- Published
- 2020
48. Importance of additional 'extreme' anterior apical needle biopsies in the initial detection of prostate cancer.
- Author
-
Moussa AS, Meshref A, Schoenfield L, Masoud A, Abdel-Rahman S, Li J, Flazoura S, Magi-Galluzzi C, Fergany A, Fareed K, and Jones JS
- Published
- 2010
- Full Text
- View/download PDF
49. Reappraisal of Morphological Differences between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-Deficient Renal Cell Carcinoma
- Author
-
Gabriella Nesi, Lakshmi P. Kunju, Gladell P. Paner, Fiona Maclean, Scott A. Tomlins, Steven C. Smith, Deepika Sirohi, Mahul B. Amin, Jonathan I. Epstein, Jesse K. McKenney, Anthony J. Gill, Adeboye O. Osunkoya, Pedram Argani, Mitual Amin, Kiril Trpkov, Ying-Bei Chen, Chisato Ohe, Abbas Agaimy, Victor E. Reuter, Michelle S. Hirsch, Eva Comperat, Priya Rao, Maurizio Colecchia, Maria M. Picken, Mariza de Peralta-Venturina, Mukul K. Divatia, Wolfram Jochum, Rohit Mehra, Isabela Werneck da Cunha, Liang Cheng, Ondřej Hes, Cristina Magi-Galluzzi, Luciana Schultz, Satish K. Tickoo, Paulo Guilherme de Oliveira Salles, Ohe, C, Smith, Sc, Sirohi, D, Divatia, M, de Peralta-Venturina, M, Paner, Gp, Agaimy, A, Amin, Mb, Argani, P, Chen, Yb, Cheng, L, Colecchia, M, Comperat, E, da Cunha, Iw, Epstein, Ji, Gill, Aj, Hes, O, Hirsch, M, Jochum, W, Kunju, Lp, Maclean, F, Magi-Galluzzi, C, Mckenney, Jk, Mehra, R, Nesi, G, Osunkoya, Ao, Picken, Mm, Rao, P, Reuter, Ve, Salles, Pgd, Schultz, L, Tickoo, Sk, Tomlins, Sa, and Trpkov, K
- Subjects
0301 basic medicine ,Male ,Pathology ,Biopsy ,DNA Mutational Analysis ,urologic and male genital diseases ,Fumarate Hydratase ,Collecting duct carcinoma ,0302 clinical medicine ,Renal cell carcinoma ,SMARCB1 ,Child ,Aged, 80 and over ,Kidney ,Kidney Medulla ,medicine.diagnostic_test ,Middle Aged ,Immunohistochemistry ,Kidney Neoplasms ,Europe ,medicine.anatomical_structure ,Phenotype ,030220 oncology & carcinogenesis ,Female ,Anatomy ,Brazil ,Adult ,medicine.medical_specialty ,Canada ,Adolescent ,Article ,Pathology and Forensic Medicine ,Renal medullary carcinoma ,Diagnosis, Differential ,03 medical and health sciences ,Young Adult ,Predictive Value of Tests ,medicine ,Carcinoma ,Biomarkers, Tumor ,Humans ,Genetic Predisposition to Disease ,Kidney Tubules, Collecting ,Carcinoma, Renal Cell ,Aged ,Retrospective Studies ,business.industry ,Australia ,medicine.disease ,United States ,030104 developmental biology ,Mutation ,Surgery ,Hereditary leiomyomatosis and renal cell carcinoma ,Neoplasm Grading ,business - Abstract
Renal Medullary Carcinomas (RMCs) and Collecting Duct Carcinomas (CDCs) are rare subsets of lethal high-stage, high-grade distal nephron-related adenocarcinomas with a predilection for the renal medullary region. Recent findings have established an emerging group of fumarate hydratase (FH)-deficient tumors related to hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC-RCCs) within this morphologic spectrum. Recently-developed, reliable ancillary testing has enabled consistent separation between these tumor types. Here, we present the clinicopathologic features and differences in the morphological patterns between RMCs, CDCs and FH-deficient RCCs in consequence of these recent developments. This study included a total of 100 cases classified using contemporary criteria and ancillary tests. Thirty-three RMCs (SMARCB1/INI1-deficient, hemoglobinopathy), 38 CDCs (SMARCB1/INI1-retained) and 29 RCCs defined by the FH-deficient phenotype (FH-/2SC+ or FH±/2SC+ with FH mutation, regardless of HLRCC syndromic stigmata/ history) were selected. The spectrum of morphologic patterns was critically evaluated and the differences between the morphological patterns present in the three groups were analyzed statistically. Twenty five percent of cases initially diagnosed as CDC were reclassified as FH-deficient RCC based on our contemporary diagnostic approach. Among the different overlapping morphologic patterns, sieve-like/cribriform and reticular/yolk sac tumor-like patterns favored RMCs, whereas intracystic papillary and tubulocystic patterns favored FH-deficient RCC. Tubulopapillary pattern favored both CDCs and FH-deficient RCCs, and multinodular infiltrating papillary pattern favored CDCs. Infiltrating glandular and solid sheets/cords/nested patterns were not statistically different among the three groups. Viral inclusion-like large nucleoli considered as a hallmark of HLRCC-RCCs were observed significantly more frequently in FH-deficient RCCs. Despite the overlapping morphology found among these clinically aggressive infiltrating high-grade adenocarcinomas of the kidney, reproducible differences in morphology emerged between these categories after rigorous characterization. Finally, we recommend that definitive diagnosis of CDC should only be made if RMC and FH-deficient RCC are excluded.
- Published
- 2018
50. Robotic Real-time Near Infrared Targeted Fluorescence Imaging in a Murine Model of Prostate Cancer: A Feasibility Study
- Author
-
Pedro F. Escobar, Warren D. W. Heston, Steve Huang, Cristina Magi-Galluzzi, Kelley M. Harsch, Sricharan Chalikonda, Georges-Pascal Haber, Robert J. Stein, Xinning Wang, Pravin K. Rao, Rakesh Khanna, Riccardo Autorino, Jihad H. Kaouk, Humberto Laydner, Wahib Isac, Bo Hu, Laydner, H, Huang, S, Heston, Wd, Autorino, Riccardo, Wang, X, Harsch, Km, Magi Galluzzi, C, Isac, W, Khanna, R, Hu, B, Escobar, P, Chalikonda, S, Rao, Pk, Haber, Gp, Kaouk, Jh, and Stein, Rj
- Subjects
Glutamate Carboxypeptidase II ,Male ,Pathology ,medicine.medical_specialty ,Fluorescence-lifetime imaging microscopy ,Infrared Rays ,Urology ,Prostate cancer cell ,Mice, SCID ,urologic and male genital diseases ,Mice ,Prostate cancer ,Mice, Inbred NOD ,Cell Line, Tumor ,medicine ,Animals ,Prostate tumors ,Fluorescent Dyes ,Membrane antigen ,Membrane Glycoproteins ,business.industry ,Optical Imaging ,Prostatic Neoplasms ,Robotics ,medicine.disease ,Fluorescent Antibody Technique, Direct ,Murine model ,Feasibility Studies ,Signal intensity ,business ,Neoplasm Transplantation - Abstract
Objective To evaluate the detection of near-infrared fluorescence from prostate tumors stained with a prostate-specific membrane antigen (PSMA)–targeted tracer developed in our institution with a novel robotic imaging system. Methods Prostate cancer cell lines PC3-pip (PSMA positive) and PC3-flu (PSMA negative) were implanted subcutaneously into 6 immunodeficient mice. When tumors reached 5 mm, a PSMA-targeted fluorescent conjugate was injected intravenously. The first 3 mice underwent near-infrared imaging immediately and hourly up to 4 hours after injection to determine the time necessary to obtain peak fluorescence and were killed. The last 3 mice were imaged once preoperatively and were euthanized 120 minutes later. Excision of the tumors was performed by using a novel robotic imaging system to detect near-infrared fluorescence in real time. Specimens were submitted for pathology. Results In the first 3 mice, we found 120 minutes as the time needed to observe peak fluorescence from the PSMA-positive tumors. We identified discrete near-infrared fluorescence from 2 of 3 PSMA-positive tumors with the robotic imaging system. Surgical margins were negative for all excised specimens except for one PSMA-negative tumor. Conclusions Real-time near-infrared fluorescence imaging of prostate cancer is feasible with a novel robotic imaging system. Further research is needed to optimize the signal intensity detectable from prostate cancer with our tracer. Toxicologic studies are needed before its clinical use.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.